Company intelligence / Profile preview

First Genomix

Ownership: Private
Development stage: Commercial

Overview

First Genomix is a leading provider of advanced genetic diagnostic services in the GCC and Middle East. The company offers comprehensive reproductive, prenatal, hereditary cancer, and rare disease testing using state-of-the-art molecular technologies such as next-generation sequencing. It was the first lab in its region to receive College of American Pathologists accreditation for NGS. The company supports healthcare providers with both testing and expert genetic counseling. No drug or therapeutic clinical results apply.

Therapeutic areas: OncologyRare DiseasesWomen's Health
Modalities: Diagnostic testNext-generation sequencing (NGS)Whole exome sequencingCarrier screeningNon-invasive prenatal testing
Industry: Molecular Diagnostics

Partnerships

Accredited by College of American Pathologists for NGS technology

Beyond the preview

Go deeper on First Genomix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on First Genomix.

Explore the full profile